The Advertising Standards Authority (ASA) has issued a significant ruling, prohibiting a series of advertisements for weight loss injections that were deemed to exploit new mothers' body image insecurities and improperly promote prescription-only medication to the general public.
Social Media Advertisements Deemed Irresponsible
The regulatory body investigated multiple Instagram and Facebook advertisements for online pharmacy Juniper, which were found to violate advertising codes. The ASA determined that these ads created an inappropriate sense of urgency for individuals considering medicated weight-loss programs and failed to clearly indicate sponsored content within weight-loss support groups.
Exploiting Vulnerable New Mothers
One particularly concerning Facebook advertisement from October featured a video showing a woman caring for her baby, walking with a pram, and posing for photographs. The accompanying caption discussed starting "a medicated weightloss journey with Juniper" and described benefits including returning confidence and energy.
The ASA questioned whether this advertisement suggested new mothers should prioritize weight loss after giving birth, concluding that it exploited their body image insecurities and reinforced harmful gender stereotypes about postpartum appearance expectations.
Company Defense and Regulatory Rejection
Juniper disputed the ASA's interpretation, claiming their intended message was that mothers could "seek a balance that felt right for them." However, the regulator maintained that the advertisement was irresponsible and breached advertising codes by promoting harmful stereotypes about body image expectations for new mothers.
Black Friday Promotions and Undue Urgency
The watchdog also examined two Instagram advertisements from November and December featuring Black Friday promotions with text urging consumers to "Run, don't walk" and highlighting savings of £179 over six months. The ASA ruled these created an undue sense of urgency for consumers considering weight-loss medication programs.
Undisclosed Advertising in Support Groups
Further violations were identified in Facebook weight-loss support groups, where posts and comments promoting Juniper's services were not clearly identifiable as advertisements. One September post compared Juniper's pricing to competitor medications, while another offered discount codes for first-time customers.
CheqUp Health, which brought these undisclosed advertisements to the ASA's attention, questioned whether they properly identified themselves as marketing material and whether they inappropriately promoted prescription-only medicines to the public.
Regulatory Action and Industry Response
The ASA has ordered Juniper to cease promoting prescription-only medicines to the public and to ensure future advertising does not create inappropriate urgency for consumers considering weight-loss programs.
CheqUp founder Toby Nicol commented on the ruling, stating: "Today's ruling highlights the need for greater clarity across the weight loss medication market. When non-compliant advertising continues to appear so visibly on fast-moving digital channels, it creates confusion for consumers and gives the impression that some practices may be permissible when they are not."
Nicol further emphasized that while advertising rules may appear established theoretically, the current framework fails to provide sufficient clarity or consistent enforcement for a rapidly evolving market category. This creates an uneven environment where responsible providers face penalties while others push regulatory boundaries.
The ASA's decision represents a significant intervention in the digital marketing of weight loss medications, particularly concerning vulnerable populations such as new mothers navigating postpartum body image concerns.
